

Table S5. Germline pathogenic variants in *BRCA1/2* among lymphoma patients and comparison with pathogenic variants in *BRCA1/2* found in other cancer types from our previous study

Chr	Pos	Ref	Alt	HGVS.c	HGVS.p	Gene	Alternative allele	Alternative allele	Cancer type
							frequency in lymphoma case (%)	frequency in control (%)	
13	32,906,627	GC	G	c.1013delC	p.Ala338fs	<i>BRCA2</i>	0.02527	0.00000	L
13	32,907,420	GA	G	c.1813delA	p.Ile605fs	<i>BRCA2</i>	0.07568	0.00399	L, FB, G, O, Pa, Pr
13	32,912,089	CTG	C	c.3599_3600delIGT	p.Cys1200fs	<i>BRCA2</i>	0.02523	0.00266	L, Pr
13	32,913,391	CTT	C	c.4903_4904delITT	p.Leu1635fs	<i>BRCA2</i>	0.02523	0.00000	L, E, FB, G
13	32,914,065	CAATT	C	c.5576_5579delTTAA	p.Ile1859fs	<i>BRCA2</i>	0.02523	0.00532	L, FB, G, O, Pa, Pr
13	32,918,775	A	T	c.6922A>T	p.Lys2308*	<i>BRCA2</i>	0.02599	0.00134	L, FB, O, Pr
13	32,918,778	AG	A	c.6926delG	p.Ser2309fs	<i>BRCA2</i>	0.02599	0.00000	L
13	32,920,978	C	T	c.6952C>T	p.Arg2318*	<i>BRCA2</i>	0.02523	0.01330	L, FB, G, O, Pa, Pr
13	32,972,800	C	T	c.10150C>T	p.Arg3384*	<i>BRCA2</i>	0.05045	0.01197	L
17	41,197,729	T	C	c.5621A>G	p.Tyr1874Cys	<i>BRCA1</i>	0.02523	0.00000	L, B, FB
17	41,215,389	C	A	c.5217G>T	p.Trp1739Cys	<i>BRCA1</i>	0.02523	0.00133	L
17	41,243,024	ACT	A	c.4120_4121delAG	p.Ser1374fs	<i>BRCA1</i>	0.02523	0.00000	L, FB, O
17	41,244,004	G	A	c.3544C>T	p.Gln1182*	<i>BRCA1</i>	0.02523	0.00133	L, FB, G
17	41,244,085	C	CT	c.3462dupA	p.Asp1155fs	<i>BRCA1</i>	0.02523	0.00000	L, G
17	41,245,157	TTC	T	c.2389_2390delIGA	p.Glu797fs	<i>BRCA1</i>	0.05045	0.00266	L, B, FB, G, O
17	41,258,497	A	T	c.188T>A	p.Leu63*	<i>BRCA1</i>	0.02523	0.01064	L, B, FB, G, O

Sixteen germline pathogenic variants of *BRCA1/2* found in this study were compared with those observed in biliary duct (*BRCA1*), female breast (*BRCA1/2*), male breast (*BRCA2*), esophageal (*BRCA2*), gastric (*BRCA1/2*), ovarian (*BRCA1/2*), pancreatic (*BRCA1/2*), and prostate cancer (*BRCA2*) carriers from our previous study.¹

Abbreviations: B, Biliary duct cancer; E, Esophageal cancer; FB, Female Breast cancer; G, Gastric cancer; L, Lymphoma; O, Ovarian cancer; Pa, Pancreatic cancer; Pr, Prostate cancer.

1. Momozawa Y, Sasai R, Usui Y, et al. Expansion of Cancer Risk Profile for *BRCA1* and *BRCA2* Pathogenic Variants. *JAMA Oncol.* 2022; 8: 871-878.